ALFA News
Straight from the exchange filing
Every announcement Biocon has filed with the exchanges that we have reported, newest first. Each story links the original filing.
Every Biocon announcement on ALFA FilingsSee filings →Reference market data from a third-party provider, as of the most recent story. Not a valuation or a recommendation.
Biocon Limited secures global launch dates for biosimilar Pebrilzo after settling with Genentech. EU launch set for Q1 2027 and US for Q3 2028 for the cancer drug.
Biocon Biologics receives Japan MHLW marketing approval for its Pegfilgrastim biosimilar. This oncology product strengthens Biocon's ₹17,321 Cr TTM revenue base.
Biocon Ltd announces the US commercial launch of Yesafili, an interchangeable biosimilar to Eylea. The product targets a US market with 19.8 million AMD patients.
